# Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

> **NCT07108153** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sionna Therapeutics Inc.** · enrollment: 16 (estimated)

## Conditions studied

- Cystic Fibrosis (CF)

## Interventions

- **DRUG:** SION-719
- **DRUG:** Placebo-to-match SION-719

## Key facts

- **NCT ID:** NCT07108153
- **Lead sponsor:** Sionna Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-03
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07108153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07108153, "Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07108153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*